CA2309609A1 - Imidazoylalkyle substitue par un noyau heterocyclique a cinq, six ou sept chainons contenant un atome d'azote - Google Patents

Imidazoylalkyle substitue par un noyau heterocyclique a cinq, six ou sept chainons contenant un atome d'azote Download PDF

Info

Publication number
CA2309609A1
CA2309609A1 CA002309609A CA2309609A CA2309609A1 CA 2309609 A1 CA2309609 A1 CA 2309609A1 CA 002309609 A CA002309609 A CA 002309609A CA 2309609 A CA2309609 A CA 2309609A CA 2309609 A1 CA2309609 A1 CA 2309609A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
independently selected
salt
trihalomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002309609A
Other languages
English (en)
Inventor
Wayne D. Vaccaro
Ronald L. Wolin
Daniel M. Solomon
Robert G. Aslanian
John J. Piwinski
Stuart B. Rosenblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2309609A1 publication Critical patent/CA2309609A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I) ou des sels ou solvates pharmaceutiquement acceptables desdits composés. On décrit des compositions pharmaceutiques comprenant un transporteur pharmaceutiquement acceptable et une quantité efficace d'un composé de la formule (I). On décrit également un procédé pour traiter une allergie (comme l'asthme), une inflammation, l'hypotension, une augmentation de la tension intraoculaire (telle que le glaucome), un procédé pour atténuer la tension intraoculaire, les troubles du sommeil, l'hyper ou hypomotilité et la sécrétion acide du tube digestif, l'hypo ou hyperactivité du système nerveux central (comme l'agitation ou la dépression), et d'autres troubles du SNC (comme la maladie d'Alzheimer, la schizophrénie, l'obésité ou la migraine). Le procédé consiste à administrer une quantité efficace d'un composé de la formule (I) à un patient nécessitant un tel traitement. On décrit enfin des procédés pour traiter des réactions allergiques de la voie aérienne supérieure, qui consistent à administrer un composé de la formule (I) ou un sel ou solvate dudit composé, en combinaison ou convenablement mélangé avec un antagoniste du récepteur H¿1? à l'histamine.
CA002309609A 1997-11-07 1998-11-05 Imidazoylalkyle substitue par un noyau heterocyclique a cinq, six ou sept chainons contenant un atome d'azote Abandoned CA2309609A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96575497A 1997-11-07 1997-11-07
US08/965,754 1997-11-07
PCT/US1998/023224 WO1999024421A1 (fr) 1997-11-07 1998-11-05 Imidazoylalkyle substitue par un noyau heterocyclique a cinq, six ou sept chainons contenant un atome d'azote

Publications (1)

Publication Number Publication Date
CA2309609A1 true CA2309609A1 (fr) 1999-05-20

Family

ID=25510440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002309609A Abandoned CA2309609A1 (fr) 1997-11-07 1998-11-05 Imidazoylalkyle substitue par un noyau heterocyclique a cinq, six ou sept chainons contenant un atome d'azote

Country Status (12)

Country Link
EP (1) EP1028956A1 (fr)
JP (1) JP2001522845A (fr)
KR (1) KR20010031839A (fr)
CN (1) CN1285828A (fr)
AR (1) AR016671A1 (fr)
AU (1) AU1296799A (fr)
CA (1) CA2309609A1 (fr)
HU (1) HUP0102662A3 (fr)
IL (1) IL135727A0 (fr)
PE (1) PE130699A1 (fr)
WO (1) WO1999024421A1 (fr)
ZA (1) ZA9810186B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
FR2827863A1 (fr) * 2001-07-27 2003-01-31 Sanofi Synthelabo Derives d'aminoalkylimidazole, leur preparation et leur utilisation en therapeutique
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
CA2550012A1 (fr) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Derives d'uree, processus de production correspondant et utilisation
HUE033441T2 (en) * 2004-12-30 2017-11-28 Janssen Pharmaceutica Nv 4- (Benzyl) piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid hydrolase (phaha) for the treatment of anxiety, pain and other diseases
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
WO2022175384A1 (fr) * 2021-02-17 2022-08-25 Fundación Universidad Católica De Valencia San Vicente Mártir Agents à petites molécules ayant une activité antivirale contre des virus à arn

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07121939B2 (ja) * 1991-12-18 1995-12-25 シェリング・コーポレーション 窒素含有４または５員複素環で置換されたイミダゾリルまたはイミダゾイルアルキル化合物
DE69212164T2 (de) * 1991-12-18 1996-12-05 Schering Corp Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
WO1995006037A1 (fr) * 1993-08-27 1995-03-02 Vrije Universiteit Nouveaux derives d'imidazoles a activite agoniste ou antagoniste du recepteur h3 a l'histamine
ATE314071T1 (de) * 1996-08-16 2006-01-15 Schering Corp Behandlung von allergischen reaktionen im oberen respirationstrakt mit einer kombination von histamin-rezeptor-antagonisten

Also Published As

Publication number Publication date
PE130699A1 (es) 1999-12-16
KR20010031839A (ko) 2001-04-16
IL135727A0 (en) 2001-05-20
WO1999024421A8 (fr) 1999-08-26
EP1028956A1 (fr) 2000-08-23
JP2001522845A (ja) 2001-11-20
HUP0102662A3 (en) 2003-01-28
WO1999024421A1 (fr) 1999-05-20
CN1285828A (zh) 2001-02-28
AR016671A1 (es) 2001-07-25
AU1296799A (en) 1999-05-31
ZA9810186B (en) 1999-05-06
HUP0102662A2 (hu) 2001-12-28

Similar Documents

Publication Publication Date Title
US6100279A (en) Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US5463074A (en) Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
EP0673928B1 (fr) Nouveaux dérivés de la N-(3,4-dichlorophényl-propyl)-pipéridine comme antagonistes sélectifs du récepteur NK3 humain
CA2125964C (fr) Derives d'imidazolylalkylpiperazine et -diazepine, agonistes/antagonistes du recepteur h3 a l'histamine
EP0619818B1 (fr) Imidazoylalkyle substitue par un cycle heterocyclique contenant de l'azote a six elements
FR2861074A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JPH06510034A (ja) アザ環式化合物、それらの製造方法、及びそれらを含む医薬組成物
WO2000053596A2 (fr) Composes imidazole substitues par un noyau heterocyclique a six ou sept membres renfermant deux atomes d'azote
EP1019373B1 (fr) Derives de 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidine comme antagonistes selectifs du recepteur nk3 humain
JP2000513383A (ja) タキキニン受容体拮抗薬２−（ｒ）−（１−（ｒ）−（３，５−ビス（トリフルオロメチル）フェニル）エトキシ）−３−（ｓ）−（４−フルオロ）フェニル−４−（３−（５−オキソ−１ｈ，４ｈ−１，２，４−トリアゾロ）メチルモルホリンの多形結晶
CA2879176C (fr) Derives triazole carboxamide
CA2309609A1 (fr) Imidazoylalkyle substitue par un noyau heterocyclique a cinq, six ou sept chainons contenant un atome d'azote
EP1028948B1 (fr) Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h 3?
US5807872A (en) Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
JPH1171350A (ja) ヒドロキシピペリジン化合物およびその剤
CA2308586A1 (fr) Ligands du recepteur h3 du type phenyl-alkyl-imidazole
US5633250A (en) Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
MXPA00004399A (en) Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
FR2717477A1 (fr) Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.

Legal Events

Date Code Title Description
FZDE Discontinued